Join a webinar with Caristo Diagnostics!

We’re hosting a live webinar with OTIF portfolio company Caristo Diagnostics on Wednesday 24th June 2020 at 17:30

The event will feature a 20-minute presentation showcasing the Company and recent developments, as well as touching on the ways the Company is supporting the fight against the COVID-19 pandemic. This will be followed by a 10-minute Q&A session with CEO Dr Cheerag Shirodaria and Academic Founder Prof Charalambos Antoniades.

Caristo Diagnostics is a medical imaging company spun out from the University of Oxford’s Department of Cardiovascular Medicine in June 2018 to commercialise a novel imaging biomarker for the prediction of cardiovascular disease (CVD) risk using CT scans of the heart. In clinical studies, this novel biomarker (the Fat Attenuation Index or FAI™) has been shown to be accurate in predicting heart attacks and cardiac death, including in those patients deemed low risk by current methods.

The webinar will be held via Zoom and further details can be found in the invitation accessible here.

We hope you can join us and would be grateful if you could RSVP using the registration link here.

If you have any queries please contact Helen at helen@oxfordinvestmentconsultants.com.

 

Important notice: This is event is being held for information purposes only. Reliance on the information in this event communication and disclosed during the event itself, for the purpose of engaging in any investment activity, may expose an individual to a risk of losing all of the funds invested. Neither this communication or the information disclosed during the event constitute, or should be considered as, an offer to buy or sell or solicitation of an offer to buy or sell any security or share. The information contained in this communication and that disclosed during the event is NOT intended for retail investors. Upon RSVP’ing to the event you will be requested to confirm that you are one of either: A High Net Worth Individual or A Sophisticated Investor. Details of what is required to qualify as a High Net Worth Individual and a Sophisticated Investor can be viewed in detail here.